Randomized Study Comparing Three Standard Treatments for Isolated Skin Vasculitis

What this Trial Is About

Researchers are evaluating the effectiveness of three standard medicationscolchicine, dapsone, and azathioprinein treating patients with isolated skin vasculitis. This randomized, multicenter trial aims to compare these treatments over a two-stage process, focusing on patients with skin-limited vasculitis conditions such as small or medium vessel vasculitis, cutaneous polyarteritis nodosa, and IgA vasculitis without significant kidney involvement. The study is sponsored by the University of Pennsylvania and is conducted as a Phase 2 trial. Participants are initially randomized to receive one of the three study drugs for six months. The primary endpoint is the response to treatment at six months. If a participant needs to stop their assigned medication due to lack of response, disease flare, or side effects within the first six months or during follow-up up to twelve months, they will be re-randomized to one of the remaining two drugs for an additional six months. Response to therapy is evaluated again at the end of this second stage. During the study, participants will undergo regular assessments including physician and patient global response evaluations, quality of life measurements, and specific skin-related questionnaires at multiple time points up to twelve months. Researchers will monitor treatment response at months 3, 6, 9, and 12, with safety and side effects carefully observed. Total participation can last up to one year, with ongoing follow-up to assess the effectiveness and tolerability of the study medications.

A Randomized Multicenter Study for Isolated Skin Vasculitis